Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Clinuvel Pharmaceuticals Ltd

CUV.AX ✗ NOT COMPLIANT ☆ Track — members

ASX · Healthcare · Pharmaceuticals ·

Australia Small Cap Analyst: BUY

Last Close

$6.76

▼ -0.42%

Market Cap $339.71M · Vol 52.53K

Key Metrics

P/E Ratio

14.83

FWD: 12.40

Market Cap

$339.71M

Small Cap

Div Yield

0.75%

Annual dividend

EPS Growth

+7.64%

YoY

RSI (14)

43.23

Momentum

Beta

0.68

vs Market

52W High

$9.91

25.76% below

52W Low

$5.91

14.91% above

Volume

52.53K

Avg 101.41K

P/B

2.16

Price-to-book

ROE

16.30%

Return on equity

Free Float

83.41%

Public shares

Shariah Compliance8 STANDARDS

✗ Clinuvel Pharmaceuticals Ltd (CUV.AX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CUV.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+1.17%

-6.28%

+0.10%

-9.91%

YTD

-23.35%

-21.91%

-48.44%

-64.93%

Financials & Valuation

TTM · Annual

Total Revenue	$62.52M
Net Income	$23.80M
Revenue Growth (YoY)	+3.60%
Gross Margin	94.04%
Operating Margin	48.13%
Net Profit Margin	38.07%
ROE	16.30%
ROA · ROIC	20.50% · 17.66%

P/E Ratio	14.83
Forward P/E (FY1)	12.40
PEG Ratio	5.15
P/S	5.50
P/B	2.16
P/FCF	12.82
EPS Growth	+7.64%
Outstanding Shares	50.43M

Technical Indicators

50-Day SMA	$6.93
200-Day SMA	$7.43
RSI (14)	43.23
Beta	0.68
52-Week High	$9.91
52-Week Low	$5.91

Volume Today	52.53K
Avg Daily Volume (30D)	101.41K
Relative Volume	0.52x
Volatility (10D)	21.45
Volatility (30D)	26.14
Free Float	83.41%

Analyst Consensus

BUY

Current Price $6.76

Mean Target $16.76

52W Low$5.91 52W High$9.91

Current

Target

$5.91 $9.91

Current Analyst target

+147.90% upside potential · 8 analysts

Identifiers

ExchangeASX

FIGIBBG001SFPXM9

ISINAU000000CUV3

CountryAustralia

Sub-IndustryBiopharmaceuticals

Earnings DateAug 26, 2026

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

REGN Regeneron Pharmaceuticals Inc -0.31% 207940.KS Samsung Biologics Co Ltd -1.02% UCB.BR Ucb SA -3.10% CSL.AX CSL Ltd -0.74% BIIB Biogen Inc -0.39%

Company Profile

Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the United States of America, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). It has operations in Europe, Singapore, and the United States of America. It develops and manufactures NEURACTHEL (adrenocorticotropic hormone) in different formulations, to target neurological, endocrinological, and degenerative disorders. Its pharmaceutical product, PRENUMBRA, has been developed, and its use is to be expanded in the clinic from stroke to Parkinson's.